Arguments prove nothing unless verified. A commentary on Kaufman's "Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example".

[1]  J. Kaufman.  Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example. , 2008, Social science & medicine.

[2]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[3]  Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. , 2004, American journal of hypertension.

[4]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[5]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[6]  M. Drazner,et al.  Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. , 2002, Journal of the American College of Cardiology.

[7]  A. P. Dawid,et al.  Commentary: Counterfactuals: help or hindrance? , 2002 .

[8]  S. Greenland,et al.  Estimating causal effects. , 2002, International journal of epidemiology.

[9]  A. Dawid.  Counterfactuals: help or hindrance? , 2002, International journal of epidemiology.

[10]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[11]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[12]  J. DeSousa.  Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy--the Canadian Implantable Defibrillator Study. , 2001 .

[13]  A J Moss,et al.  Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. , 2000, Circulation.

[14]  S. Saha.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[15]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[16]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[17]  S Greenland,et al.  Matching and efficiency in cohort studies. , 1990, American journal of epidemiology.